Rare disease clinical trials: Power in numbers

Matthew P Wicklund, Matthew P Wicklund

Abstract

The limb-girdle muscular dystrophies (LGMDs) encompass a collection of genetic muscle diseases with proximal-predominant weakness of the limbs. Thirty-two of these disorders are named via the common nomenclature, including 8 autosomal-dominant (LGMD1A-H) and 24 autosomal-recessive (LGMD2A-X) disorders.(1) In addition, numerous other genetic muscle diseases, including Bethlem myopathy, dystrophinopathies, ryanodine receptor-associated myopathies, and many more, may clinically present with similar proximal-predominant weakness.(2) Therefore, current genetic testing panels targeting neuromuscular weakness frequently encompass >75 genes. These disorders are quite rare, each with minimum prevalence estimates of 0.01-0.60 cases per 100,000 persons.(3) LGMD2A (attributable to mutations in the gene for calpain-3) and LGMD2B (attributable to mutations in the gene for dysferlin) consistently are the 2 most prevalent LGMD subtypes in a variety of ethnic cohorts.

References

    1. Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myologica 2014;33:1–12.
    1. Gordon ES, Hoffman EP. The ABC's of limb-girdle muscular dystrophy: α-sarcoglycanopathy, Bethlem myopathy, calpainopathy and more. Curr Opin Neurol 2001;14:567–573.
    1. Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009;132:3175–3186.
    1. Harris E, Bladen CL, Mayhew A, et al. . The Clinical Outcome Study for dysferlinopathy: an international multicenter study. Neurol Genet 2016;2:e89. doi: .
    1. Nilsson MI, Laureano ML, Saeed M, Tarnopolsky MA. Dysferlin aggregation in limb-girdle muscular dystrophy type 2B/Myoshi myopathy necessitates mutational screen for diagnosis. Muscle Nerve 2013;47:740–747.
    1. Walter MC, Reilich P, Thiele S, et al. . Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 2013;8:26.
    1. Narayanaswami P, Weiss M, Selcen D, et al. . Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology 2014;83:1453–1463.
    1. Sondergaard PC, Griffin DA, Pozsgai ER, et al. . AAV.dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol 2015;2:256–270.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi